

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV524614996 US
Express Mail Label Number2/25/05
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1206

COPPOLA ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP 03/03466

FILED: 2 APRIL 2003

U.S. APPLICATION NO: 10/510,026

35 USC §371 DATE: 16 DECEMBER 2004

FOR: 5-SUBSTITUTED 1,1-DIOXO-1,2,5-THIADIAZOLIDIN-3-ONE
DERIVATIVES**Mail Stop: PCT**Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists the "**Foreign Applications**" and the "**Title**".

The instant application claims benefit of the provisional applications that are listed under the foreign applications section. The provisional applications are U.S. applications and should be removed from the foreign applications section and listed under the "**Domestic Priority data as claimed by applicant**" section and inserted directly under the International application.

The **title** was changed by Applicants in a Preliminary Amendment, dated October 1, 2004 (a copy of the first and second pages are enclosed herewith) after they noted some errors in the title given in the International stage of the application. Please issue a corrected filing receipt listing the domestic priority data and the title as follows:


-- Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/03466 04/02/2003
which claims benefit of 60/369930 04/03/2002
and claims benefit of 60/369,779 04/03/2002 --.

-- Title 5-Substituted 1,1-dioxo-1,2,5-thiadiazolidin-3-one derivatives --.

A copy of the filing receipt with the correction noted is enclosed.

Respectfully submitted,



Paivi Kukkola
Agent for Applicants
Reg. No. 50,499

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7875
PK/dd

Encl. copy of first and second pages of Preliminary Amendment, dated October 1, 2004
copy of filing receipt

Date: February 24, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

COPPOLA ET AL.

INTERNATIONAL APPLICATION NO: PCT/ EP 03/03466

FILED: 2 APRIL 2003

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: 5-SUBSTITUTED 1,1-DIOXO-1,2,5-THIADIAZOLIDIN-3-ONE
DERIVATIVES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above-referenced patent application, please enter the following preliminary amendment.

Amendments to the specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of the claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 28 of this paper.

Amendments to the Specification:

Please correct the title to read as follows:

5-SUBSTITUTED 1,1-DIOXO-1,2,5-THIADIAZOLIDIN-3-ONE DERIVATIVES

Page 1, please insert the following paragraph directly beneath the title:

This application claims the benefit of U.S. provisional application No. 60/369,930, filed April 3, 2002 and U.S. provisional application No. 60/369,779, filed April 3, 2002, the contents of which are incorporated herein by reference.

Please add the Abstract attached hereto as a separate page on the end of the specification.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/510,026	12/16/2004	1734	1206	PC/4-32444A		27	1

1095
NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER, NJ 07936-1080

CONFIRMATION NO. 4647

FILING RECEIPT



OC000000014881771

PJK

Date Mailed: 01/06/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Gary Mark Coppola, Budd Lake, NJ;
John William Davies, Winchester, MA;
Charles Francis Jewell Jr, Sudbury, MA;
Yu-Chin Li, Edison, NJ;
James Richard Wareing, Stow, MA;
Donald Mark Sperbeck, Berkeley Heights, NJ;
Travis Mathew Stams, Stow, MA;
Sidney Wolf Topiol, Fair Lawn, NJ;
Isidoros Vlattas, Summit, NJ;



Power of Attorney:

Paivi Kukkola-50499

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/03466 04/02/2003

Foreign Applications

UNITED STATES OF AMERICA 60369930 04/03/2002
UNITED STATES OF AMERICA 60369779 04/03/2002

needs correcting

Projected Publication Date: 04/14/2005

Non-Publication Request: No

Early Publication Request: No

Title

5-Substituted 1,1-dioxo-^{thiadiazolidin}1,2,5-thiazolidine-3-one derivatives ^{delete} [as ptpase 1b inhibitors]

Preliminary Class

034

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).